Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Neumann

Showing results (21-30 of 301) with videos related to

Pageof 31
Sort By:
Health Affairs (Project Hope)|September 10, 2009
Is the United States ready for QALYs?Peter J Neumann, Dan Greenberg
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 31, 2002
FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violationKate A Stewart, Peter J Neumann
The New England Journal of Medicine|April 8, 2011
Listening to Provenge--what a costly cancer treatment says about future Medicare policyJames D Chambers, Peter J Neumann
JAMA Network Open|October 22, 2021
Valuing Alzheimer Disease Therapies-Considering Costs and Benefits Beyond the PatientPei-Jung Lin, Peter J Neumann
The New England Journal of Medicine|October 15, 2010
Legislating against use of cost-effectiveness informationPeter J Neumann, Milton C Weinstein
The New England Journal of Medicine|August 21, 2023
Turning CMS into a Health Technology Assessment OrganizationPeter J Neumann, Sean R Tunis
Annals of Internal Medicine|November 5, 2019
Comparative Modeling to Inform Health Policy Decisions: A Step ForwardDavid D Kim, Peter J Neumann
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 11, 2013
Is the US "leading from behind" on health policy?Peter J Neumann, Cayla J Saret
Expert Review of Pharmacoeconomics & Outcomes Research|October 22, 2013
A survey of individuals in US-based pharmaceutical industry HEOR departments: attitudes on policy topicsPeter J Neumann, Cayla J Saret
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 18, 2008
Decision analytic models for Alzheimer's disease: state of the art and future directionsJoshua T Cohen, Peter J Neumann
Pageof 31

Showing results (21-30 of 301) with videos related to

Sort By:
Pageof 31
Health Affairs (Project Hope)|September 10, 2009
Is the United States ready for QALYs?Peter J Neumann, Dan Greenberg
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 31, 2002
FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violationKate A Stewart, Peter J Neumann
The New England Journal of Medicine|April 8, 2011
Listening to Provenge--what a costly cancer treatment says about future Medicare policyJames D Chambers, Peter J Neumann
JAMA Network Open|October 22, 2021
Valuing Alzheimer Disease Therapies-Considering Costs and Benefits Beyond the PatientPei-Jung Lin, Peter J Neumann
The New England Journal of Medicine|October 15, 2010
Legislating against use of cost-effectiveness informationPeter J Neumann, Milton C Weinstein
The New England Journal of Medicine|August 21, 2023
Turning CMS into a Health Technology Assessment OrganizationPeter J Neumann, Sean R Tunis
Annals of Internal Medicine|November 5, 2019
Comparative Modeling to Inform Health Policy Decisions: A Step ForwardDavid D Kim, Peter J Neumann
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 11, 2013
Is the US "leading from behind" on health policy?Peter J Neumann, Cayla J Saret
Expert Review of Pharmacoeconomics & Outcomes Research|October 22, 2013
A survey of individuals in US-based pharmaceutical industry HEOR departments: attitudes on policy topicsPeter J Neumann, Cayla J Saret
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 18, 2008
Decision analytic models for Alzheimer's disease: state of the art and future directionsJoshua T Cohen, Peter J Neumann
Pageof 31